499 related articles for article (PubMed ID: 25490234)
21. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
22. The emerging role of CXC chemokines and their receptors in cancer.
Vinader V; Afarinkia K
Future Med Chem; 2012 May; 4(7):853-67. PubMed ID: 22571611
[TBL] [Abstract][Full Text] [Related]
23. Cancer stem cells as a target population for drug discovery.
Bouvard C; Barefield C; Zhu S
Future Med Chem; 2014 Sep; 6(14):1567-85. PubMed ID: 25367391
[TBL] [Abstract][Full Text] [Related]
24. Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries.
Gozalbes R; Simon L; Froloff N; Sartori E; Monteils C; Baudelle R
J Med Chem; 2008 Jun; 51(11):3124-32. PubMed ID: 18479119
[TBL] [Abstract][Full Text] [Related]
25. Drug discovery process for kinase inhibitors.
Weinmann H; Metternich R
Chembiochem; 2005 Mar; 6(3):455-9. PubMed ID: 15742380
[No Abstract] [Full Text] [Related]
26. The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.
Essegian D; Khurana R; Stathias V; Schürer SC
Cell Rep Med; 2020 Oct; 1(7):100128. PubMed ID: 33205077
[TBL] [Abstract][Full Text] [Related]
27. Advances at the intersection of chemical biology and medicinal chemistry.
Tavassoli A
Future Med Chem; 2015; 7(16):2089-90. PubMed ID: 26571116
[No Abstract] [Full Text] [Related]
28. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Jin M; Wang J; Buck E; Mulvihill MJ
Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
[TBL] [Abstract][Full Text] [Related]
29. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).
Tan L; Nomanbhoy T; Gurbani D; Patricelli M; Hunter J; Geng J; Herhaus L; Zhang J; Pauls E; Ham Y; Choi HG; Xie T; Deng X; Buhrlage SJ; Sim T; Cohen P; Sapkota G; Westover KD; Gray NS
J Med Chem; 2015 Jan; 58(1):183-96. PubMed ID: 25075558
[TBL] [Abstract][Full Text] [Related]
30. Modulation of Kinases by Small Molecules for Therapeutic Management of Various Diseases - Part II.
Bharate SB
Curr Top Med Chem; 2020; 20(17):1521. PubMed ID: 32830621
[No Abstract] [Full Text] [Related]
31. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
Park H; Chi O; Kim J; Hong S
J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
[TBL] [Abstract][Full Text] [Related]
32. 25 years of small molecular weight kinase inhibitors: potentials and limitations.
Fabbro D
Mol Pharmacol; 2015 May; 87(5):766-75. PubMed ID: 25549667
[TBL] [Abstract][Full Text] [Related]
33. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.
Rippin I; Khazanov N; Shirley Ben Joseph ; Kudinov T; Berent E; Arciniegas Ruiz SM; Marciano D; Levy L; Gruzman A; Senderowitz H; Eldar-Finkelman H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218072
[TBL] [Abstract][Full Text] [Related]
34. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm.
Fu RG; Sun Y; Sheng WB; Liao DF
Eur J Med Chem; 2017 Aug; 136():195-211. PubMed ID: 28494256
[TBL] [Abstract][Full Text] [Related]
35. A small molecule inhibits protein disulfide isomerase and triggers the chemosensitization of cancer cells.
Eirich J; Braig S; Schyschka L; Servatius P; Hoffmann J; Hecht S; Fulda S; Zahler S; Antes I; Kazmaier U; Sieber SA; Vollmar AM
Angew Chem Int Ed Engl; 2014 Nov; 53(47):12960-5. PubMed ID: 25256790
[TBL] [Abstract][Full Text] [Related]
36. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
37. Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.
George DM; Breinlinger EC; Friedman M; Zhang Y; Wang J; Argiriadi M; Bansal-Pakala P; Barth M; Duignan DB; Honore P; Lang Q; Mittelstadt S; Potin D; Rundell L; Edmunds JJ
J Med Chem; 2015 Jan; 58(1):222-36. PubMed ID: 25000588
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
39. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
Lawrence HR; Mahajan K; Luo Y; Zhang D; Tindall N; Huseyin M; Gevariya H; Kazi S; Ozcan S; Mahajan NP; Lawrence NJ
J Med Chem; 2015 Mar; 58(6):2746-63. PubMed ID: 25699576
[TBL] [Abstract][Full Text] [Related]
40. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
